Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

55 results about "Antimitotic Agent" patented technology

An agent that inhibits tumor growth by interfering with mitotic processes or the assembly of the mitotic machinery.

Benzimidazole derivatives and their use as KDR kinase protein inhibitors

The invention discloses and claims benzimidazole compounds of formula (I): wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitiotic agents.
Owner:AVENTIS PHARMA SA (US)

Method for Diagnosing, Prognosing and Treating Glioma

InactiveUS20070141066A1Long median patient survivalShort overall survivalHeavy metal active ingredientsCompound screeningAbnormal tissue growthAnti mitotic
The invention provides generally a method of monitoring, diagnosing, prognosing and treating glioma. Specifically, the invention provides for three (3) prognostic subclasses of glioma, which are differentially associated with activation of the akt and notch signaling pathways. Tumor displaying neural or proneural PN lineage markers (including notch pathway elements) show longer median patient survival, while the two remaining tumor markers Prolif and Mes are associated with shortened survival. Tumors classified in this manner may also be treated with the appropriate PN- Prolif- or Mes-therapeutic corresponding to the subclassification in combination with anti-mitotic agents, anti-angiogenic agents, Akt antagonists, and neural differentiation agents. Alternatively, the invention also provides for method of prognosing and diagnosing glioma with a two-gene model based on the expression levels of PTEN and DLL3.
Owner:GENENTECH INC

Disposable sheath for specula

A speculum sheath which covers a speculum and methods for using the sheath are described herein. A variety of different types of specula may be covered with the sheath, including anal, vaginal, ear, and nasal specula. The sheath is made of a compliant or partially compliant material, including latex, vinyl, natural and synthetic rubbers, silicone, nylon, polyethylene, polypropylene, and non-degradable or degradable elastomers. The material may be transparent or opaque. In the preferred embodiment, the material is transparent. The sheath may contain one or two openings. Optionally, the sheath contains an affixing means on the inside of or at least one of the openings on the sheath to prevent slippage when in contact with the speculum. Optionally, the sheath contains an active agent, such as hemostatic agents, anti-infectives, antibiotics, antimitotics anti-inflammatory, or other chemotherapeutic agents. In the preferred embodiment, the sheath is placed on a vaginal speculum and supports loose vaginal tissue when inserted into a patient. In the most preferred embodiment, the material is transparent so that medical provider may view the lumen.
Owner:ENDOLUMINAL THERAPEUTICS

Embossed texture decorative mortar as well as preparation and construction methods thereof

The invention discloses embossed texture decorative mortar which is dry-mixed mortar prepared by mechanically stirring cement, sand, auxiliary materials, emulsion powder, cellulose ether, an antimitotic agent, an expanding agent and other functional auxiliaries according to a certain proportion. The embossed texture decorative mortar prepared by the invention has the characteristics such as high strength after being hardened, good toughness, impact resistance, durability and roller coating property, elegant decorative effect, high texture and the like so as to be suitable for forming various three-dimensional concave-convex decorative effects.
Owner:天津市科垣新型建材有限公司 +1

Anti-mitotic agent and aurora kinase inhibitor combination as Anti-cancer treatment

The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.
Owner:SCHERING CORP

Extra-light porous thermal insulating material and method for preparing same

The invention relates to an extra-light porous thermal insulating material and a method for preparing the same. The extra-light porous thermal insulating material is prepared from the following components by mass percent through mixing: 65-80% of cement, 5-25% of metakaolin, 5-15% of micro-silica, 3-6% of foamer, 0.5-2% of foam stabilizer, 0.2-0.6% of antimitotic agent and 0.5-2% of excitant. The method for preparing the extra-light porous thermal insulating material comprises the steps of: pretreating the cement, preparing the metakaolin, preparing the foam stabilizer, preparing the antimitotic agent, preparing the excitant and preparing the thermal insulating material. The method provided by the invention is significant in improving the thermal insulation property, fireproofing property, safety and durability of a building; and simultaneously, the provided thermal insulating material has the advantages of low dry density, low coefficient of heat conductivity and high strength.
Owner:WUHAN UNIV OF TECH

Method for diagnosing, prognosing and treating glioma

The invention provides generally a method of monitoring, diagnosing, prognosing and treating glioma. Specifically, the invention provides for three (3) prognostic subclasses of glioma, which are differentially associated with activation of the akt and notch signaling pathways. Tumor displaying neural or proneural PN lineage markers (including notch pathway elements) show longer median patient survival, while the two remaining tumor markers Prolif and Mes are associated with shortened survival. Tumors classified in this manner may also be treated with the appropriate PN- Prolif- or Mes- therapeutic corresponding to the subclassification in combination with anti-mitotic agents, anti-angiogenic agents, Akt antagonists, and neural differentiation agents. Alternatively, the invention also provides for method of prognosing and diagnosing glioma with a two- gene model based on the expression levels of PTEN and DLL3.
Owner:GENENTECH INC

Synthetic diazonamides as novel anti-mitotic agents

The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate Diazona angulata useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Anti-cracking sulphate aluminium cement plant fiber product and preparing method thereof

The invention discloses an anti-cracking sulphate aluminium cement plant fiber product, being prepared from the following component raw materials in parts by weight: sulphate aluminium cement, bits of wood, silica fume, coal ash, glass fiber, water, retarder, water-retaining agent, thickener and antimitotic agent. The preparing method comprises: (1) weighing the respective component raw materials in parts by weight; (2) adding the sulphate aluminium cement, bits of wood, silica fume, coal ash and glass fiber in to water and stirring, adding the water-retaining agent, thickener and antimitotic agent and stirring, standing; (3) adding the retarder, stirring, conveying into a roller level production workshop, entering a template, filling, performing roller leveling to produce a wet panel, cutting, and then conveying into a curing workshop for curing. The product has a smooth surface, no cracks, no cracking phenomenon, high strength and high durability; further, the product has easily obtained raw materials and low cost and the preparing method is low in cost and easy and simple to operate.
Owner:ZHUODA NEW MATERIALS TECH GRP WEIHAI CO LTD

Mgmt inhibitor combination for the treatment of neoplastic disorders

InactiveUS20100093647A1Good effectEnhancing both mitotic catastrophe and apoptosisBiocideOrganic chemistryDiseaseAntimitotic Agent
A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.
Owner:CASE WESTERN RESERVE UNIV

Additive for spraying plastering mortar

The invention relates to an additive for spraying plastering mortar. The additive is prepared from the following raw materials in parts by weight: 50-65 parts of a thickening thickener, 2-8 parts of an air entraining agent, 15-40 parts of a strength excitant, 2-10 parts of a thickening time control agent and 20-45 parts of an expansive antimitotic agent, wherein the thickening thickener is selected from one or more of polyacrylamide, redispersible powder, polyvinyl alcohol, hydroxymethyl cellulose ether, carboxymethylcellulose ether and the like; and the air entraining agent is selected from one or more of sodium dodecyl sulfate, sodium abietate and triterpenoid saponin. According to the additive provided by the invention, the mortar has sprayability and can be firmly attached to the wall space and is not sticky to a cutter, so that leveling construction is facilitated.
Owner:林立(武汉)新能源科技有限公司

Use Of N-(4-((3-(2-Amino-4-Pyrimidinyl)-2-Pyridinyl)Oxy)Phenyl)-4-(4-Methyl-2-Thienyl)-1-Phthalazinamine In The Treatment Of Antimitotic Agent Resistant Cancer

The present invention relates to methods of using the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl) -1-phthalazinamine, to treat cancers, including solid tumors, which have become resistant to treatment with chemotherapeutic agents, including anti-mitotic agents such as taxanes, and / or other anti-cancer agents, including aurora kinase inhibiting agents. The invention also includes methods of treating cancers refractory to such treatments by administering a pharmaceutical composition, comprising the compound to a cancer subject.
Owner:AMGEN INC

Compound-doped mineral admixture for reinforced concrete structure of oceanographic engineering

The invention relates to the field of concrete additives for oceanographic engineering, and aims at providing a compound-doped mineral admixture for a reinforced concrete structure of the oceanographic engineering. The compound-doped mineral admixture comprises the following components in percentage by mass: 20 to 35% of coal ash, 5 to 10% of zeolite, 20 to 40% of slag, 5 to 15% of silica fume, 5 to 15% of corrosion inhibitor, 2 to 5% of dispersing agent, 0 to 10% of shrinkage reducing agent, and 0 to 16% of antimitotic agent. According to the compound-doped mineral admixture, multi-component design is adopted, the functions of all the components are combined and coordinated, and thus the crack resistance and rust resistance of the structure are optimized, and the wear resistance of the oceanographic engineering can be improved; and a plurality of functional components are compounded into the admixture, so that the functional components can be uniformly dispersed in the concrete, and the effects of stably resisting crack and resisting rust can be realized. The compound-doped mineral admixture can reduce the concrete agitating conditions and reduce the usage cost of an enterprise, and is convenient for massive popularization and application.
Owner:浙江合力海科新材料股份有限公司

Genetic variations associated with drug resistance

Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and / or overexpressed in the cancer.
Owner:GENENTECH INC

Light heat insulation construction material of solar energy phase transition heat accumulation

The invention relates to a light heat insulation construction material of solar energy phase transition heat accumulation, which has the following technical essentials: firstly, respectively adding acertain amount of phase transition heat accumulation and heat insulation material, common portland cement, fly ash, light expanded vermiculite powder, expanded water-hardened steel slag and cement reinforcing agent sequentially into a mixing trough; evenly mixing the materials by stirring at normal temperature; then, adding with stirring, a certain amount of impervious waterproof agent, redispersible latex powder as a bonding regulator, polypropylene cellulose as an antimitotic agent, starch ether and chlordene powder or SQ-8 algicide trichloro-propyl sulfate as an anti-mildew agent; fully mixing the materials evenly by cyclone separation; and packing the mixture to obtain a finished product. The material of the invention has good effects of heat insulation, heat accumulation and energy saving, light volume weight (345-650 kilograms / cubic meter), large density, high strength and small heat transfer coefficient. The fly ash which is a serious public nuisance is fully utilized as a renewable resource to produce the environment-friendly light heat insulation construction material of solar energy phase transition heat accumulation by fully utilizing the characteristics of the fly ash.
Owner:沈阳隆发电热产品制造有限公司

Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment

The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.
Owner:SCHERING AG

Waterproof coating and preparation method thereof

InactiveCN103387358AProtection against erosionSeepage will not occurAntimitotic AgentWater soluble
The invention relates to waterproof coating. The formula of the waterproof coating comprises the following components in parts by weight: 10-30 parts of powder, 25-50 parts of cement, 1-5 parts of latex powder and 0.1-1 part of a polypropylene antimitotic agent, wherein the powder is prepared by steps of mixing and stirring anhydrous sodium sulfate and water soluble silicone oil, and then filtering, drying and crushing; and the mass ratio of the anhydrous sodium sulfate to the water soluble silicone oil is 1:1. The waterproof coating effectively solves the problems of cracking, water seepage, easy falling and single property of the traditional wall surface covering layer. By the waterproof coating, water seepage of the wall is avoided under dry or moist and water-seeping condition, and the wall can be effectively protected from being eroded by rainwater, does not crack after being exposed to the sun, wind and rain for a long time and is ventilated under the dry condition. The waterproof coating has excellent adhesive performance and facilitates construction.
Owner:张国宏

Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents

A method of screening a tumour cell for resistance to a tubulin-binding agent, the method comprising detecting the expression of any one or more of class II, class III and class IVb ss-tubulin by the tumour cell, wherein the expression of any one or more of class II, class III and class IVb ss-tubulin indicates that the tumour cell has resistance or potential resistance to the tubulin-binding agent.
Owner:NEWSOUTH INNOVATIONS PTY LTD

Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors

The present invention relates to a method for treating solid cancers including non-small 5 cell lung cancer, pancreatic, bladder, breast and ovarian cancer as well as advanced biliary tract cancers comprising administering at least one antineoplasticagent such as a nucleotide analog, for example gemcitabine, or an antimitotic such as docetaxel, in combination with a tyrosine kinase inhibitor selected from 2-aminoarylthiazoles and 2-aminoaryloxazoles.
Owner:AB SCIENCE

Modified chalcone compounds as antimitotic agents

InactiveUS7714025B2Imparts antimitotic and antitumor characteristicEnhanced interactionBiocideOrganic chemistryThiolAntimitotic Agent
Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN—COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an α,β-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and / or disappearance of the cancer, to the benefit of cancer patients.
Owner:ARIZONA BIOMEDICAL RES COMMISSION

Screening, diagnosis, prognostication and treatment of ovarian cancer

Methods and uses relating to diagnosing ovarian cancer or determining the risk of atypical proliferative epithelial lesions or tumours progressing to invasive ovarian cancer or the risk of recurrent non-invasive disease by detecting a loss-of-function-related genetic alteration in the PAPPA gene or the absence or reduced level of functional PAPPA or an increased proportion of mitotic cells (prophase or prometaphase). Therapeutic aspects enable the sensitisation of mitotically delayed ovarian cancer cells to antiproliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis, wherein a first therapeutic agent is applied to release ovarian cancer cells from the mitotic block and a second therapeutic agent or therapy affecting proliferating cells is administered to kill the cycling cancer cells.
Owner:AFG TECH

Targeted polymeric nano-complexes as drug delivery system

InactiveUS20170128592A1Increase phospho-Histone H expressionDepolymerizePowder deliveryEther/acetal active ingredientsAnticarcinogenMedicine
The present invention provides targeted polymeric nano-complexes for delivery of drugs such as anti-mitotic agents or anti-cancer agents. The present invention also provides a process for the preparation of such targeted nano-complexes.
Owner:INDIAN INST OF TECH

Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors

The present invention relates to a method for treating solid cancers including non-small 5 cell lung cancer, pancreatic, bladder, breast and ovarian cancer as well as advanced biliary tract cancers comprising administering at least one antineoplasticagent such as a nucleotide analog, for example gemcitabine, or an antimitotic such as docetaxel, in combination with a tyrosine kinase inhibitor selected from 2-aminoarylthiazoles and 2-aminoaryloxazoles.
Owner:AB SCIENCE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products